SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-041137
Filing Date
2023-11-14
Accepted
2023-11-14 16:19:09
Documents
14
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40847
2 ex99-1.htm EX-99.1 39423
3 ex99-1_001.jpg GRAPHIC 3650
  Complete submission text file 0001493152-23-041137.txt   269761

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aneb-20231114.xsd EX-101.SCH 3012
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aneb-20231114_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aneb-20231114_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3564
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 231406635
SIC: 2834 Pharmaceutical Preparations